-
Company Insights
Innovation and Patenting activity of GNI Group Ltd Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of GNI Group Ltd Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewPulmonary Radiation Toxicity – Drugs In Development, 2024
Empower your strategies with our Pulmonary Radiation Toxicity  – Drugs In Development, 2024 report and make more profitable business decisions. Radiation lung toxicity encompasses any lung toxicity induced by radiation therapy (RT). Damage to normal lung tissue in the individuals. There is a damage to normal lung tissue, to overcome this there is aa image-guided radiotherapy and the use of agents to reduce lung injury from radiation. The Pulmonary Radiation Toxicity drugs in development market research report provide comprehensive information...
-
Product Insights
NewAcute Promyelocytic Leukemia – Drugs In Development, 2024
Empower your strategies with our Acute Promyelocytic Leukemia – Drugs In Development, 2024 report and make more profitable business decisions. Acute Promyelocytic Leukemia is an aggressive blood cancer affecting the white blood cells known as promyelocytes which are immature white blood cells. It is characterized by thrombocytopenia (low platelets) resulting in thrombosis, excess bleeding, and anemia. It is a sub type of AML (acute myeloid leukemia) and is a medical emergency condition. Infections, bruises, bleeding are common symptoms and when examined...
-
Product Insights
NewPleural Disease – Drugs In Development, 2024
Empower your strategies with our Pleural Disease – Drugs In Development, 2024 report and make more profitable business decisions. Pleural disorders encompass a spectrum of conditions affecting the protective tissue surrounding the lungs and lining the chest cavity. Within this category, three distinct types emerge—namely pleurisy, pleural effusion, and pneumothorax—each with diverse etiologies. Characterized by inflammation of the pleura, pleurisy stands as a primary manifestation. Conversely, pleural effusion and pneumothorax result from factors such as infection, medical conditions, or chest trauma,...
-
Product Insights
NewDermatomyositis – Drugs In Development, 2024
Empower your strategies with our Dermatomyositis – Drugs In Development, 2024 report and make more profitable business decisions. Dermatomyositis is a rare inflammatory disease characterized by chronic muscle inflammation accompanied by muscle weakness. Symptoms of dermatomyositis include a distinctive skin rash, muscle weakness, and inflammatory myopathy, or inflamed muscles. Risk factors include age and gender. Treatment includes corticosteroids. The Dermatomyositis drugs in development market research report provide comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage...
-
Product Insights
NewAcute On Chronic Liver Failure (ACLF) – Drugs In Development, 2024
Empower your strategies with our Acute On Chronic Liver Failure (ACLF) – Drugs In Development, 2024 report and make more profitable business decisions. Acute-on-chronic liver failure occurs in patients with chronic liver disease and is characterized by acute deterioration of the patient requiring hospitalization and is associated with (1) hepatic and extrahepatic organ dysfunction, (2) systemic inflammation, and (3) a high 28-day mortality rate. The Acute On Chronic Liver Failure (ACLF) drugs in development market research report provide comprehensive information on...
-
Product Insights
NewAcute Liver Failure – Drugs In Development, 2024
Empower your strategies with our Acute Liver Failure – Drugs In Development, 2024 report and make more profitable business decisions. Acute liver failure is a rare but life-threatening condition that occurs when the liver loses most of its function in a short period of time. It can be caused by various factors, such as viral infections, drug overdose, autoimmune diseases, or metabolic disorders. Some of the common signs and symptoms of acute liver failure are jaundice, bleeding, confusion, and coma. Acute...
-
Product Insights
NewInterstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial lung disease (ILD) is a term that covers a variety of disorders that cause scarring or inflammation of the lung tissue. The scarring or inflammation affects the ability of the lungs to transfer oxygen to the blood. ILD can be caused by many factors, such as exposure to environmental toxins, certain medications, autoimmune diseases, infections, or...
-
Product Insights
NewLiver Failure (Hepatic Insufficiency) – Drugs In Development, 2024
Empower your strategies with our Liver Failure (Hepatic Insufficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea, and loss of appetite. Since these symptoms are associated with...